Your browser doesn't support javascript.
SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria
Clinical Immunology Communications ; 2022.
Article in English | ScienceDirect | ID: covidwho-2031197
ABSTRACT
Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study;their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.
Keywords

Full text: Available Collection: Databases of international organizations Database: ScienceDirect Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Clinical Immunology Communications Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: ScienceDirect Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Clinical Immunology Communications Year: 2022 Document Type: Article